Mativ
Valuation each multiple against its own 5-year range
Vs. peers Specialty Chemicals
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Mativ (MATV) | 640.21M | 7.07 | 1.36 | 3.45% |
| Linde (LIN) | 222.99B | 31.21 | 5.71 | 1.28% |
| Ecolab (ECL) | 79.01B | 37.83 | 7.86 | 1.01% |
| Sherwin-Williams (SHW) | 77.53B | 29.46 | 20.11 | 1.00% |
| Air Products & Chemicals (APD) | 62.63B | -1,339.33 | 4.51 | 2.56% |
| PPG Industries (PPG) | 23.11B | 14.87 | 2.74 | 2.73% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 50.8% below Morningstar's fair value estimate.
Fair value
Mativ Holdings Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 32% discount to our quantitative fair value estimate of $17.50 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 71.8% lies in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.
The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's sales yield of 304.7%, a core component of profitability, falls in the top 20% globally. This company has a robust ability to generate sales without much capital investment, freeing up more capital to be returned to shareholders in the long run. This characteristic further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-09 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mativ discussion 0 comments